SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

– Statistically significant results in primary and key secondary endpoints

– Risdiplam is the first SMA treatment to have positive placebo-controlled data in pivotal studies across a real world population of infants, children, teenagers and adults-

SOUTH PLAINFIELD, N.J., February 6, 2020 PTC Therapeutics, Inc. today announced that positive 1 year clinical data from Part 2 of the pivotal SUNFISH study evaluating risdiplam in people aged 2-25 years with nonambulatory type 2 and type 3 spinal muscular atrophy (SMA) were presented at the 2nd International SMA Europe Conference.

The study demonstrated that the change from baseline in the primary endpoint Motor Function Measure scale (MFM-32) was significantly greater in patients receiving risdiplam compared to placebo (1.55 point mean difference; p=0.0156) at 12 months of treatment. As expected, the age-related effect was notable and consistent with SMA disease progression, with younger patients (2-5 years) (78.1% vs 52.9% achieving ≥3 point increase) showing clear improvement relative to placebo while older patients demonstrated disease stabilization and, in some cases, improvement. Safety for risdiplam was consistent with its known safety profile and no new safety signals were identified.

“The results of this ambitious study confirm risdiplam’s potential to be the most competitive global product for a broad range of SMA patients,” said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics.

Current approved treatments only address a portion of SMA patients. This was the first clinical study encompassing SMA patients representative of the population that are seen in clinical practice. Together with the positive data from the FIREFISH study in type 1 patients, these data exemplify the potential of risdiplam for all SMA patients.

SUNFISH is a two-part, double-blind, placebo-controlled, pivotal study in people aged 2-25 years (n=180) with type 2 and 3 SMA, with broad inclusion criteria. The majority of patients in the study were older, had more progressed disease as evidenced by severe scoliosis and contractures, and had lower baseline scores on motor function scales relative to other clinical trials in this patient population. The primary endpoint for Part 2 was change at 12 months in motor function as measured by the MFM-32 scale compared to placebo. The MFM-32 scale is a highly sensitive, validated measure used to evaluate fine and gross motor function and is a more relevant measure for patients who have more progressed disease.

  • The pivotal, Part 2 component of the study met its primary endpoint (cut-off date: Sep 6, 2019). Total mean change from baseline in the MFM-32 score was significantly greater in patients receiving risdiplam compared to those treated with placebo at 12 months (p=0.0156).
    • The strongest responses in MFM-32 compared to placebo were observed in the youngest age group (2-5 years) (78.1% vs 52.9% achieving ≥3 point increase) as expected.
    • Stabilization, which is the goal of treatment in the older age group (18-25 years) with more established disease, was achieved versus placebo (57.1% vs 37.5%, with stabilisation defined as a ≥0 point increase).
  • Medically meaningful and statistically significant results were demonstrated in key secondary endpoints.
  • Revised Upper Limb Module (RULM) mean change from baseline was significantly greater in patients receiving risdiplam compared with placebo (1.59 point difference; p=0.0028).
  • In the Hammersmith Functional Motor Scale Expanded (HFMSE) there was a numerical difference in favour of risdiplam which did not reach statistical significance (p=0.3015).
  • Patients and caregivers also reported numerical improvements in independence as measured by the SMA Independence Scale, a new measurement that captures highly relevant, day-to-day activities such as eating and drinking, getting dressed, and overall hygiene, amongst many other daily activities. Patients and caregivers reported improvements in independence after treatment with risdiplam over 12 months (Caregiver (for all patients), p=0.0022; Patients (≥12 years), p=0.1778).
  • More than 400 patients have been treated with risdiplam across all studies to date, with no treatment-related safety findings leading to study withdrawal in any risdiplam trial. The adverse event profile was similar to placebo. The most common adverse events were upper respiratory tract infection (31.7%), nasopharyngitis (25.8%), pyrexia (20.8%), headache (20%), diarrhea (16.7%), vomiting (14.2%) and cough (14.2%). While the rate of lower respiratory tract infections overall was similar in both treatment arms (RIS 19%, PLB 20 %), serious lower respiratory tract infections occurred in more patients in the risdiplam group (RIS 10%, PLB 2%) but were reported as unrelated to risdiplam and resolved without change to study treatment.

Risdiplam (RG7916), is an investigational, oral, first-in-class, mRNA splicing modifier for the treatment of SMA. Recently, positive results from the pivotal single-arm FIREFISH Part 2 study, which assessed the efficacy of risdiplam in 41 infants (eligible age at enrollment between 1 and 7 months) with type 1 SMA treated for 12 months, were announced. The SMA programme is a collaboration between PTC, the SMA Foundation, and Roche.

In November 2019, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) and granted Priority Review for risdiplam. The NDA filing was based on 12-month data from the dose-finding, Part 1 of the pivotal FIREFISH and SUNFISH studies, and preclinical pharmacokinetic and clinical and pharmacodynamic data in all types of SMA. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is May 24, 2020.

About Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common genetic cause of infant mortality and one of the most common rare diseases, affecting approximately one in 11,000 babies. SMA leads to the progressive loss of nerve cells in the spinal cord that control muscle movement. Depending on the type of SMA, an individual’s physical strength and their ability to walk, eat or breathe can be significantly diminished or lost.

SMA is caused by a mutation in the survival motor neuron 1 (SMN1) gene that results in a deficiency of SMN protein. SMN protein is found throughout the body and increasing evidence suggests SMA is a multi-system disorder and the loss of SMN protein may affect many tissues and cells, which can stop the body from functioning.

About risdiplam

Risdiplam is an investigational survival motor neuron2 (SMN2) splicing modifier for SMA and is an orally administered liquid. It is designed to durably increase and sustain SMN protein levels both throughout the central nervous system and in peripheral tissues of the body. Risdiplam is being studied in a broad clinical trial programme in SMA, with patients ranging from birth to 60 years old, and includes patients previously treated with other SMA-targeting therapies. The clinical trial population represents the broad, real-world spectrum of people living with this disease. The risdiplam clinical development programme was designed with the aim of enabling access for all appropriate patients.

Risdiplam is currently being evaluated in four multicentre trials in people with SMA:

  • SUNFISH (NCT02908685) – SUNFISH is a two-part, double-blind, placebo-controlled pivotal study in people aged 2-25 years with types 2 or 3 SMA. Part 1 (n=51) determined the dose for the confirmatory Part 2. Part 2 (n=180) evaluated motor function using total score of Motor Function Measure 32 (MFM-32) at 12 months. MFM-32 is a validated scale used to evaluate fine and gross motor function in people with neurological disorders, including SMA.
  • FIREFISH (NCT02913482) – an open-label, two-part pivotal clinical trial in infants with type 1 SMA. Part 1 was a dose-escalation study in 21 infants. The primary objective of Part 1 was to assess the safety profile of risdiplam in infants and determine the dose for Part 2. Part 2 is a pivotal, single-arm study of risdiplam in 41 infants with type 1 SMA treated for 24 months, followed by an open-label extension. Enrollment for Part 2 was completed in November 2018. The primary objective of Part 2 is to assess efficacy as measured by the proportion of infants sitting without support after 12 months of treatment, as assessed in the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development – Third Edition (BSID-III) (defined as sitting without support for 5 seconds).
  • JEWELFISH (NCT03032172) – an open-label exploratory trial in people with SMA aged 6 months–60 years who have been previously treated with SMA-directed therapies. The study has completed recruitment.
  • RAINBOWFISH (NCT03779334) – an open-label, single-arm, multicentre study, investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of risdiplam in babies (~n=25), from birth to six weeks of age (at first dose) with genetically diagnosed SMA who are not yet presenting with symptoms. The study is currently recruiting.

About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.